Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study için istatistikler
Toplam ziyaret
| views | |
|---|---|
| Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study | 5 |
Aylık toplam ziyaret
| views | |
|---|---|
| Kasım 2024 | 0 |
| Aralık 2024 | 0 |
| Ocak 2025 | 0 |
| Şubat 2025 | 1 |
| Mart 2025 | 0 |
| Nisan 2025 | 4 |
| Mayıs 2025 | 0 |
Dosya Ziyaretleri
| views | |
|---|---|
| paz-ares-et-al-2024-sacituzumab-govitecan-versus-docetaxel-for-previously-treated-advanced-or-metastatic-non-small-cell.pdf | 4 |
